S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
NYSE:MRK

Merck & Co., Inc. - MRK Stock Forecast, Price & News

$88.39
+0.84 (+0.96%)
(As of 10/4/2022 05:37 PM ET)
Add
Compare
Today's Range
$87.00
$88.65
50-Day Range
$84.53
$92.08
52-Week Range
$71.50
$95.72
Volume
7.37 million shs
Average Volume
10.95 million shs
Market Capitalization
$223.92 billion
P/E Ratio
13.54
Dividend Yield
3.15%
Price Target
$98.33

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.68 Rating Score
Upside/​Downside
11.5% Upside
$98.33 Price Target
Short Interest
Healthy
0.77% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
0.60mentions of Merck & Co., Inc. in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-2.18%
From $7.33 to $7.17 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

69th out of 1,087 stocks

Pharmaceutical Preparations Industry

23rd out of 546 stocks

MRK stock logo

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Stock News Headlines

10 Best Diversified Dividend Stocks to Buy Now
What This News Means for Merck
10 Analysts Have This to Say About Merck & Co
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
11 Best Dividend Paying Stocks To Buy Now
Bear Market: 2 Safe Stocks to Buy Right Now
Merck Animal Health To Buy Vence; Financial Terms Not Disclosed
See More Headlines
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Company Calendar

Ex-Dividend for 7/8 Dividend
6/14/2022
Dividend Payable
7/08/2022
Last Earnings
7/28/2022
Ex-Dividend for 10/7 Dividend
9/14/2022
Today
10/04/2022
Dividend Payable
10/07/2022
Next Earnings (Confirmed)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
68,000
Year Founded
1891

Price Target and Rating

Average Stock Price Forecast
$98.33
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+11.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.68
Research Coverage
19 Analysts

Profitability

Net Income
$13.05 billion
Pretax Margin
32.40%

Debt

Sales & Book Value

Annual Sales
$48.70 billion
Cash Flow
$7.51 per share
Book Value
$15.14 per share

Miscellaneous

Outstanding Shares
2,533,280,000
Free Float
2,525,933,000
Market Cap
$223.92 billion
Optionable
Optionable
Beta
0.31

Social Links


Key Executives

  • Mr. Kenneth C. FrazierMr. Kenneth C. Frazier (Age 67)
    Exec. Chairman
    Comp: $4.58M
  • Mr. Robert M. Davis J.D.Mr. Robert M. Davis J.D. (Age 55)
    Pres, CEO & Director
    Comp: $4.4M
  • Ms. Caroline LitchfieldMs. Caroline Litchfield (Age 53)
    Exec. VP & CFO
    Comp: $2.05M
  • Mr. Richard R. DeLuca Jr.Mr. Richard R. DeLuca Jr. (Age 59)
    Exec. VP & Pres of Merck Animal Health
    Comp: $2.05M
  • Dr. Dean Y. Li M.D. (Age 60)
    Ph.D., Exec. VP & Pres of Merck Research Laboratories
    Comp: $2.4M
  • Mr. David Michael Williams (Age 53)
    Exec. VP and Chief Information & Digital Officer
  • Mr. Peter Dannenbaum
    VP of Investor Relations
  • Ms. Jennifer L. Zachary (Age 44)
    Exec. VP & Gen. Counsel
  • Lisa LeCointe-Cephas (Age 40)
    Sr. VP and Chief Ethics & Compliance Officer
  • Ms. Jennifer Mauer
    VP of Global Communications













MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 7 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRK shares.
View MRK analyst ratings
or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2022?

19 Wall Street research analysts have issued 1-year price objectives for Merck & Co., Inc.'s stock. Their MRK share price forecasts range from $85.00 to $110.00. On average, they predict the company's stock price to reach $98.33 in the next year. This suggests a possible upside of 11.1% from the stock's current price.
View analysts price targets for MRK
or view top-rated stocks among Wall Street analysts.

How have MRK shares performed in 2022?

Merck & Co., Inc.'s stock was trading at $76.64 at the start of the year. Since then, MRK stock has increased by 15.5% and is now trading at $88.50.
View the best growth stocks for 2022 here
.

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our MRK earnings forecast
.

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, October 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Thursday, July, 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. The company had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a trailing twelve-month return on equity of 48.45%. The business's quarterly revenue was up 28.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.31 earnings per share.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, July 26th. Stockholders of record on Thursday, September 15th will be given a dividend of $0.69 per share on Friday, October 7th. This represents a $2.76 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date of this dividend is Wednesday, September 14th.
Read our dividend analysis for MRK
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.20%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 42.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 38.49% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $7.25-$7.35 for the period, compared to the consensus estimate of $7.36. The company issued revenue guidance of $57.50 billion-$58.50 billion, compared to the consensus revenue estimate of $58.10 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include Cacti Asset Management LLC (0.03%), Thomasville National Bank (0.01%), M&R Capital Management Inc. (0.00%), Lynch & Associates IN (0.00%), Park National Corp OH (0.00%) and Red Spruce Capital LLC (0.00%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $88.50.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $224.20 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $6.53 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

The company employs 68,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.